Nanometer zinc oxide (Nano-ZnO) has been widely applied in many fields such as rubber,ceramics,textile,cosmetics,etc.due to its excellent physical,chemical and biological properties.In recent years,its applications in biomedicine have been paid more and more attention.This paper introduces the unique optical,chemical,mechanical,semi-conducting and biological properties of Nano-ZnO.Meanwhile,the applications of Nano-ZnO in bio-sensing and detection,biological nutrition,medical treatment,biological imaging,drug delivery,tumor cells targeted killing and translational medicine are also reviewed,and the brief outlook on the applications is presented.

[Objective]Modify Xuejiejiawei Granule judgment toxic particles to guide its clinical drug safety.[Method]Make different dosages,give the mouse to fill stomach,from the observing mouse's physiological condition to judging the medicine toxic.[Result]36 mice after given the medicine observation period do not have an example to die,after the dissection the internal organs have non-pathological changes.[Conclusion] Looking at Xuejiejiawei Granule from the medicine toxic effect,the Xuejie adding the taste pellet is a safe medicine.

AIM: To select the proper excipients for granule of compound Saliva Miltiorrhiza and the preparative process. METHODS: Building up properties, solubility and resistance to humid were used as the judgement criteria, the kinds and ratio of the excipients and preparative process sieved out. RESULTS: Properere excipent combination consisted of one portion of the extract of compound Salvia Miltiorrhiza, 1.6 times dextin, 2.6% CMC Na, 1% PVP, 2.6% CMS Na. CONCLUSION: The process and its excipent combination is better than the other process of formulation.

Objective: To explore the quality of life and drug toxicity in NSCLC (non-small cell lung cancer) patients who have a ECOC (Eastern Cooperative Oncology Group)-PS (performance status) score ≥3 and a response to gefitinib more than 6 months, and to explore the possibily of gefitinib applying in NSCLC patients with a ECOG-PS score ≥3. Methods: NSCLC patients histologically and (or) cytologically confirmed were divided into trial group (ECOG-PS score ≥3) and control group (ECOG-PS score ≤2). The patients in the two groups were treated with a dose of 250 mg/d gefitinib. The efficacy, change of quality of life and the toxicity were evaluated. Results: Eighty-eight NSCLC patients were enrolled in this study (trial group: n = 27; control group: n = 61). The median follow-up time was 20.0 months. All patients in the two groups could be évaluable. In the trial group, 4 (14.81%) patients obtained CR (complete response), 20 (74.07%) patients obtained PR (partial response), 3 (11.11%) patients obtained SD (stable disease); the response rate was 88.89% (24/27). In the control group, 10 (16.39%) patients obtained CR (complete response), 43 (70.49%) patients obtained PR (partial response), 8 (13.11%) patients obtained SD (stable disease); the response rate was 86.89% (53/61). There was no difference in response rate between the two groups (P = 0.794). The median time to symptom improvement of the trial group and the control group were 10.0 and 14.0 d, respectively (P = 0.073), the median PFS (progression-free survival) were 8.0 and 7.0 momths, respectively (P = 0.421). The 1-, 2- and 3-year survival rates were 59.269% (16/27), 25.93% (7/27) and 3.70% (1/27) in the trial group and 57.38% (35/61), 21.31% (13/61) and 6.56% (4/61), respectively. There was no difference in survival rate between the two groups (P = 0.180). The ECOG-PS score after gefitinib therapy (vs before gefitinib therapy) was significantly decreased in the two groups (Trial group Z = -4.062, P = 0.000; Control group Z = -4.031, P = 0.000), and the percent decrease of ECOG-PS score after gefitinib therapy in the trial group was significantly higher as compared with that in the control group. The toxicities of gefitinib therapy were tolerated. Conclusion: Gefitinib can be safely applied in NSCLC patients with ECOG-PS score ≥3. There is no difference in survival time between NSCLC patients with ECOG-PS score ≥3 and ≤2, but the quality of life in NSCLC patients with ECOG-PS score 2= 3 is significantly impoved as compard with NSCLC patients with ECOG-PS score ≤2 after gefitinib therapy. Copyright © 2013 by TUMOR.

Aged ; Humans ; Immunoglobulin M ; Liver Failure, Acute ; etiology ; Male ; Multiple Myeloma ; complications ; immunology

Objective To observe the efficacy of folic acid combined with mecobalamine for the treatment of vascular mild cogni-tive impairment (VMCI) in patients with cerebral small vessel disease (SVD) and hyperhomocysteinemia(Hcy) .Methods A total of 84 VMCI patients with cerebral small vessel disease and Hcy were randomly divided into combination group and control group . Two groups received conventional therapy for 6 months .Besides ,the combination group received folic acid combined with mecobal-amin .The level of plasma Hcy and ADAS-cog score were observed before and after 3 months and 6 months treatment .Results Af-ter treatment ,plasma Hcy significantly lower in the combination group (P<0 .01) ,whereas it did not show any improvement in the control group .ADAS-cog scores in combination group decreased compared with that of before treatment ,but there was no statisti-cally significant difference after 3 months treatment(P>0 .05) .However ,after 6 months treatment ,the ADAS-cog scores decreased obviously than that in the before treatment group (P<0 .05) .ADAS-cog scores in control group increased compared with before treatment ,but there was no statistically significant difference in after treatment (P>0 .05) .After 3 months treatment ,there was no significant difference on ADAS-cog score between combination group and control group (P>0 .05) ,however ,there had significant difference between the two groups after 6 months treatment(P<0 .05) .Conclusion The level of plasma Hcy could be reduced by adding folic acid and mecobalamin .Treatment of hyperhomocysteinemia may delay the progression of vascular cognitive impairment w hich caused by cerebral small vessel disease .

AIM: To analyze the effect of myopic adolescents wearing orthokeratology lens on the corneal surface curvature radius and anterior chamber depth.METHODS: Totally 120 cases of adolescent myopia were selected, among them 58 cases with 116 eyes were divided into 11-14 years old group and 62 cases with 124 eyes were 15-18 years old group according to the age.They were treated with long-term orthokeratology lens treatment, and two groups of patients were observed before wearing lens(T0), wearing for 6mo (T1), 12mo (T2) for uncorrected visual acuity, the average refractive degree improvement, the central corneal thickness, corneal curvature changes and the incidence of complications.RESULTS: The uncorrected visual acuity of the two groups at 12mo after wearing were better than that at 6mo which was better than that before wearing;the diopter had the same trend.The uncorrected visual acuity and the diopter of the 11-14 years old group at 6 and 12mo was better than those of 15-18 years old group with significant difference (P<0.05).The central corneal thickness of the two groups at 12mo after wearing were less than that at 6mo which was less than that before wearing.There was no significant difference of the central corneal thickness between the two groups at 6 and 12mo after wearing (P>0.05).The corneal anterior surface curvature of the two groups at 12mo after wearing were more than that at 6mo which was more than that before wearing.The axial length of the 11-14 years old group was longer than that of the 15-18 years old group with significant difference (P<0.05).There was no significant difference on the corneal posterior surface curvature of the two groups before and after wearing (P>0.05).There was no significant difference on the anterior chamber depth between the two groups at different time or between before and after wearing (P>0.05).CONCLUSION: Long-term wearing orthokeratology lenses have a significant effect for control ling juvenile myopia, and can improve the corneal anterior surface curvature, especially in the lower age group, and has no significant effect on the anterior chamber depth.

AIM:To study the clinical effect of silica gel drainage tube combined with lomefloxacin hydrochloride eye ophthalmic gel in the treatment of lacrimal duct obstruction.METHODS:Totally 86 cases (138 eyes) of lacrimal duct embolism treated in our hospital from February to December 2015 were divided into 43 cases (68 eyes) as control group and 43 cases (70 eyes) of the observation group according to whether they were treated with lomefloxacin hydrochloride eye ophthalmic gel.Patients in the control group were treated with silica gel drainage, while the observation group was treated with lomefloxacin hydrochloride eye ophthalmic gel on the basis of the control group.The total effective rate, serum hypersensitivity C-reactive protein (h-CRP) level, complications and recurrence rate were observed and compared between the two groups.RESULTS:The total effective rate in the patients with obstructive nasolacrimal duct, common lacrimal duct obstruction, and lacrimal duct obstruction in observation group were 95.2%, 100.0%, 96.7%, higher than those in control group (P<0.05).There was no significant difference between the two groups in preoperative serum h-CRP levels (P>0.05).The serum levels of h-CRP in patients in the observation group at 3d and 7d after operation respectively were 2.40±0.84g/mL, 1.94±0.84g/mL, lower than those of control group at the same time (P<0.05).The complication rate of the observation group was 1.4%, which was lower than that of the control group (P<0.05).Follow up for 6-18mo, the recurrence rate was 11.4% in the observation group, which was significantly lower than the control group (P<0.05).CONCLUSION:The combination of silica gel drainage tube and lomefloxacin hydrochloride eye ophthalmic gel in the treatment of obstruction of lacrimal duct has good clinical efficacy, low inflammatory reaction, low complication rate and low recurrence rate.

Objective To study the TCM syndrome distribution and characteristics of pregnant patients with cold in Panzhihua region;To provide evidence for prevention and treatment of this disease.Methods Totally 107 pregnant patients with cold were analyzed to obtain TCM syndrome data and summarize the distribution and characteristics of this disease.Results The syndromes of 107 cases of pregnancy cold, from high to low were sore throat (64.49%), thirst (62.62%), nasal congestion (61.68%), cough (59.81%), runny nose (55.15%), and defense phase symptoms such as sore throat, thirst and nasal congestion were obvious. The main TCM syndrome was wind-heat syndrome, accounting for 82.24%. The incidence rates of early pregnancy (<12weeks), midtrimester pregnancy (13-27 weeks), and late pregnancy (>28 weeks) were 32.71% (35/107), 44.86% (48/107), and 22.43% (24/107), respectively. The incidence rates of early pregnancy and midtrimester pregnancy were higher than that of late pregnancy (P<0.05). The incidence rates were 53.27% (57/107) in spring and summer and 46.73% (50/107) in autumn and winter, with statistical significance (P<0.01). The incidence of wind-heat syndrome in spring and summer was 62.5% (55/88),Conclusion The most common syndrome in pregnancy cold was wind-heat syndromes. The most common characteristics were warm, hot and dry. Early or middle pregnant patients were more likely to catch cold in spring and summer. The syndrome distribution and characteristics were relevant to local environment and climate factors.

Objective:To investigate the protective effect of pine pollen on lipopolysaccharide (LPS)-induced learning and memory impairments in mice and the underlying mechanism.Methods:Sixty mice were randomly divided into four groups ( n = 15/group): normal control, model, low-dose pine pollen (500 mg/kg) and high-dose pine pollen (1 000 mg/kg). Mouse models of learning and memory impairment were established by lateral ventricle injection of LPS. The learning and memory abilities of mice were determined by the Morris water maze test. Superoxide dismutase (SOD) activity and glutathione (GSH) and malondialdehyde (MDA) levels in the hippocampus of mice were measured. Interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), dopamine (DA), and norepinephrine (NE) levels in the hippocampus were also determined. Results:The latency in the passive avoidance test in the model group was significantly shorter than that in the normal control group [(134.80 ± 33.89) s vs. (282.20 ± 17.43) s, t = 4.23, P < 0.01]. The number of errors in the model group was significantly higher than that in the normal control group [(4.00 ± 1.58) vs. (1.20 ± 1.30) times, t = 2.85, P < 0.01]. The latency in the passive avoidance test in the low-dose pine pollen (500 mg/kg) and high-dose pine pollen (1000 mg/kg) groups was significantly longer than that in the normal control group [(189.40 ± 27.21) s or (213.40 ± 21.26) s vs. (134.80 ± 33.89) s, t = 3.21, 4.38, all P < 0.05]. The number of errors in the low-dose pine pollen (500 mg/kg) and high-dose pine pollen (1 000 mg/kg) groups was significantly lower than that in the normal control group [(1.60 ± 1.44) times or (1.40 ± 1.44) times vs. (4.00 ± 1.58) times, t = 5.12, 6.42, both P < 0.05]. SOD activity and GSH, DA and NE levels in the hippocampus in the model group were significantly decreased compared with the normal control group [SOD: (7.59 ± 1.77) kU/g vs. (39.90 ± 6.37) kU/g; GSH: (3.49 ± 0.13) mmol/g vs. (6.37 ± 0.14) mmol/g; DA: (418.42 ± 2.57) ng/L vs. (586.37 ± 3.64) ng/L; NE: (187.20 ± 5.41) ng/L vs. (298.42 ± 2.32) ng/L, t = 3.67, 8.23, 2.23, 3.65, all P < 0.05]. MDA, IL-6 and TNF-α levels in the hippocampus in the normal control group were significantly higher than those in the model group [MDA: (8.79 ± 0.82) mmol/g vs. (2.62 ± 0.16) mmol/g, IL-6: (48.07 ± 5.56) ng/L vs. (18.76 ± 1.42) ng/L, TNF-α: (87.20 ± 4.31) ng/L vs. (22.42 ± 3.39) ng/L, t = 7.45, 2.67, 4.35, P < 0.05 or P < 0.01]. SOD activity, GSH, DA and NE levels in the hippocampus in the low-dose pine pollen (500 mg/kg) and high-dose pine pollen (1 000 mg/kg) groups were significantly higher than those in the model group [SOD: (18.80 ± 2.39) kU/g, (28.70 ± 2.36) kU/g vs. (7.59 ± 1.77) kU/g, GSH: (5.04 ± 0.36) mmol/g, (5.45 ± 0.17) mmol/g vs. (3.49 ± 0.13) mmol/g, DA: (488.37 ± 3.46) ng/L, (506.29 ± 5.72) ng/L vs. (418.42 ± 2.57) ng/L, NE: (225.65 ± 3.72) ng/L, (239.76 ± 5.58) ng/L vs. (187.20 ± 5.41) ng/L, t = 4.56 or 6.71, t = 4.65 or 5.32, t = 4.73 or 6.72, t = 3.84 or 5.63, P < 0.05 or P < 0.01]. MDA, IL-6 and TNF-α levels in the hippocampus in the low-dose pine pollen (500 mg/kg) and high-dose pine pollen (1 000 mg/kg) groups were significantly lower than those in the model group [MDA: (5.72 ± 0.47) mmol/g, (3.77 ± 0.23) mmol /g vs. (8.79 ± 0.82) mmol/g, IL-6: (28.42 ± 3.54) ng/L, (23.43 ± 5.62) ng/L vs. (48.07 ± 5.56) ng/L, TNF-α: (48.87 ± 4.82) ng/L, (39.65 ± 6.69) ng/L vs. (87.20 ± 4.31) ng/L, t = 6.31 or 7.28, t = 3.46 or 6.31, t = 4.28 or 3.57, P < 0.05 or P < 0.01]. Conclusion:Pine pollen can improve LPS-induced learning and memory impairments possibly through up-regulating the levels of monoamine neurotransmitters DA and NE and inhibiting the levels of oxidative stress and inflammatory reaction in the hippocampus of mice.